Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.

@article{Vlay1986IntravenousAO,
  title={Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.},
  author={S. Vlay and G. Mallis},
  journal={American heart journal},
  year={1986},
  volume={111 3},
  pages={
          452-5
        }
}
  • S. Vlay, G. Mallis
  • Published 1986
  • Medicine
  • American heart journal
  • Twenty-eight subjects underwent evaluation of drug toxicity and antiarrhythmic efficacy with oral and intravenous lorcainide. Lorcainide, a new type 1C antiarrhythmic drug, has an active metabolite, norlorcainide, which accumulates after oral but not significantly after intravenous administration. Group 1 consisted of 14 subjects who received intravenous lorcainide with an initial bolus of 2 mg/kg at a rate of 2 mg/min followed by 0.14 mg/min or 200 mg/24 hours. The lorcainide level after bolus… CONTINUE READING
    3 Citations

    References

    SHOWING 1-10 OF 20 REFERENCES
    Disposition and antiarrhythmic effect of lorcainide.
    • 29
    Lorcainide; II. Plasma concentration‐effect relationship
    • 60
    Lorcainide disposition kinetics in arrhythmia patients
    • 26